



BREATHTEC TO COMPLETE SHARE CONSOLIDATION

VANCOUVER, BC – (October 16, 2018) – Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “**Company**”) is pleased to announce that further to its news release dated August 2, 2018, the Company will consolidate its common shares on a two (2) for one (1) basis and will begin trading on the Canadian Securities Exchange on a post-consolidated basis effective October 17, 2018 (the “**Share Consolidation**”). The Company currently has 57,897,356 common shares issued and outstanding. Following the Share Consolidation, the Company will have approximately 28,948,678 common shares issued and outstanding. The new CUSIP number will be 10639L200 and the new ISIN number will be CA10639L2003.

Upon completion of the Share Consolidation, a letter of transmittal will be sent by mail to registered shareholders. The letter of transmittal will contain instructions on how registered shareholders can exchange their share certificates or DRS statements evidencing their pre-consolidated common shares for new share certificates or new DRS statements representing the number of post-consolidated common shares to which they are entitled. No action is required by non-registered shareholders (shareholders who hold their shares through an intermediary) to effect the Share Consolidation.

ABOUT BREATHTEC BIOMEDICAL INC.

Breathtec Biomedical, Inc. was formed to propel innovative research in the area of airborne analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of certain pathogens. Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry. For more information, visit www.breathtecbiomedical.com.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Breathtec BioMedical Inc.
604.398.4175 ext 701
info@breathtechbiomedical.com
investors@breathtecbiomedical.com
www.breathtecbiomedical.com

The CSE has not reviewed, approved or disapproved the content of this press release.